-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...
An analog-to-digital converter (ADC) IP core employing a time-interleaved pipeline architecture is now available for white-box licensing with no royalty fees, full modification rights, and unlimited ...
Greetings. Welcome to Sutro Biopharma R&D Day 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Jane Chung, CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback